BBS-Bioactive Bone Substitutes (OHEL:BONEH) Operating Income : €-3.39 Mil (TTM As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BBS-Bioactive Bone Substitutes Operating Income?

BBS-Bioactive Bone Substitutes's Operating Income for the six months ended in Jun. 2024 was €-1.59 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was €-3.39 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. BBS-Bioactive Bone Substitutes's Operating Income for the six months ended in Jun. 2024 was €-1.59 Mil. BBS-Bioactive Bone Substitutes's Revenue for the six months ended in Jun. 2024 was €0.00 Mil. Therefore, BBS-Bioactive Bone Substitutes's Operating Margin % for the quarter that ended in Jun. 2024 was %.

BBS-Bioactive Bone Substitutes's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BBS-Bioactive Bone Substitutes's annualized ROC % for the quarter that ended in Jun. 2024 was -31.02%. BBS-Bioactive Bone Substitutes's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -362.00%.

BBS-Bioactive Bone Substitutes Operating Income Historical Data

The historical data trend for BBS-Bioactive Bone Substitutes's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BBS-Bioactive Bone Substitutes Operating Income Chart

BBS-Bioactive Bone Substitutes Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Income

Get a 7-Day Free Trial

-1.54

-2.65

-2.57

-2.95

-3.37

BBS-Bioactive Bone Substitutes Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Operating Income	Get a 7-Day Free Trial												-1.48	-1.47	-1.57	-1.79	-1.59

BBS-Bioactive Bone Substitutes Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-3.39 Mil.

BBS-Bioactive Bone Substitutes (OHEL:BONEH) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BBS-Bioactive Bone Substitutes's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-3.182 * ( 1 - 0% )	/	( (9.732	+	10.783)	/ 2 )
=	-3.182	/	10.2575
=	-31.02 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.613	-	0.239	-	( 1.971	-	max(0, 1.377	-	2.019	+	1.971	))
=	9.732

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.374	-	0	-	( 0.85	-	max(0, 2.295	-	0.886	+	0.85	))
=	10.783

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

BBS-Bioactive Bone Substitutes's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.182	/	( ( (0.901 + max(-0.575, 0))	+	(0.821 + max(0.036, 0)) )	/	2 )
=	-3.182	/	( ( 0.901	+	0.857 )	/	2 )
=	-3.182	/	0.879
=	-362.00 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.239	+	0	+	0.336)
=	-0.575

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.039	+	0	+	-0.003)	-	(0	+	0	+	0)
=	0.036

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

BBS-Bioactive Bone Substitutes's Operating Margin % for the quarter that ended in Jun. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-1.591	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

BBS-Bioactive Bone Substitutes Operating Income Related Terms

Thank you for viewing the detailed overview of BBS-Bioactive Bone Substitutes's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

BBS-Bioactive Bone Substitutes Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BBS-Bioactive Bone Substitutes PLC (OHEL:BONEH) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kiviharjunlenkki 6, Oulu, FIN, 90220

Website

https://www.bbs-artebone.fi

BBS-Bioactive Bone Substitutes PLC) is a biomedical technology company that develops, manufactures, and commercializes innovative, bioactive medical devices and implants for orthopaedic surgery, and develops, designs, and manufactures bioactive bone-graft substitute implants. Its ortho-biological product ARTEBONE, which is based on tricalcium phosphate and a natural spectrum of bone proteins has the capability of bone regeneration.

BBS-Bioactive Bone Substitutes Headlines

No Headlines